TLR4 inhibitor resatorvid provides neuroprotection in experimental traumatic brain injury: Implication in the treatment of human brain injury

Neurochemistry International

Volumn 75, Issue , 2014, Pages 11-18

  Zhang, Dingding ^a   Li, Hua ^a   Li, Tao ^a   Zhou, Mengliang ^a   Hao, Shuangying ^b   Yan, Huiying ^a   Yu, Zhuang ^a   Li, Wei ^a   Li, Kuanyu ^b   Hang, Chunhua ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Apoptosis; Resatorvid; Toll like receptor 4; Traumatic brain injury

Indexed keywords

CASPASE 3; INTERLEUKIN 1BETA; RESATORVID; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; ETHYL 6-(N-(2-CHLORO-4-FLUOROPHENYL)SULFAMOYL)CYCLOHEX-1-ENE-1-CARBOXYLATE; NEUROPROTECTIVE AGENT; SULFONAMIDE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CONTUSION; BRAIN DAMAGE; BRAIN TISSUE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DISEASE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN INJURIES; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOLOGY;

ANIMALS; APOPTOSIS; BRAIN INJURIES; HUMANS; MALE; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; SULFONAMIDES; TOLL-LIKE RECEPTOR 4;

EID: 84901774483     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2014.05.003     Document Type: Article

References (30)

1. A. Adeleye, E. Shohami, D. Nachman, A. Alexandrovich, V. Trembovler, R. Yaka, Y. Shoshan, J. Dhawan, and A. Biegon d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window Eur. J. Pharmacol. 629 2010 25 30
2. A. Adhikari, M. Xu, and Z.J. Chen Ubiquitin-mediated activation of TAK1 and IKK Oncogene 26 2007 3214 3226 (Pubitemid 46763016)
3. A. Ahmad, R. Crupi, M. Campolo, T. Genovese, E. Esposito, and S. Cuzzocrea Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice PLoS One 8 2013 e57208
4. A. Biegon, P.A. Fry, C.M. Paden, A. Alexandrovich, J. Tsenter, and E. Shohami Dynamic changes in N-methyl-d-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits Proc. Natl. Acad. Sci. U.S.A. 101 2004 5117 5122 (Pubitemid 38469212)
5. C.C. Chen, T.H. Hung, Y.H. Wang, C.W. Lin, P.Y. Wang, C.Y. Lee, and S.F. Chen Wogonin improves histological and functional outcomes, and reduces activation of TLR4/NF-kappaB signaling after experimental traumatic brain injury PLoS One 7 2012 e30294
6. G. Chen, S. Zhang, J. Shi, J. Ai, M. Qi, and C. Hang Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway Exp. Neurol. 216 2009 398 406
7. R.S. Clark, P.M. Kochanek, S.C. Watkins, M. Chen, C.E. Dixon, N.A. Seidberg, J. Melick, J.E. Loeffert, P.D. Nathaniel, K.L. Jin, and S.H. Graham Caspase-3 mediated neuronal death after traumatic brain injury in rats J. Neurochem. 74 2000 740 753 (Pubitemid 30053747)
8. R. Diaz-Arrastia, P.M. Kochanek, P. Bergold, K. Kenney, C. Marx, J. Grimes, Y. Loh, G. Adam, D.B. Oskvig, K. Curley, and W. Salzer Pharmacotherapy of traumatic brain injury: state of the science and the road forward report of the department of defense neurotrauma pharmacology workgroup J. Neurotrauma 2013
9. T. Goldmann, P. Wieghofer, P.F. Muller, Y. Wolf, D. Varol, S. Yona, S.M. Brendecke, K. Kierdorf, O. Staszewski, M. Datta, T. Luedde, M. Heikenwalder, S. Jung, and M. Prinz A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation Nat. Neurosci. 16 2013 1618 1626
10. M. Ii, N. Matsunaga, K. Hazeki, K. Nakamura, K. Takashima, T. Seya, O. Hazeki, T. Kitazaki, and Y. Iizawa A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling Mol. Pharmacol. 69 2006 1288 1295
11. S.V. Kabadi, B.A. Stoica, M. Hanscom, D.J. Loane, G. Kharebava, M.G. Murray Ii, R.M. Cabatbat, and A.I. Faden CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury Neurotherapeutics 9 2012 405 421
12. T. Kawamoto, M. Ii, T. Kitazaki, Y. Iizawa, and H. Kimura TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain Eur. J. Pharmacol. 584 2008 40 48
13. A.R. Klatt, G. Klinger, O. Neumuller, B. Eidenmuller, I. Wagner, T. Achenbach, T. Aigner, and E. Bartnik TAK1 downregulation reduces IL-1beta induced expression of MMP13, MMP1 and TNF-alpha Biomed. Pharmacother. 60 2006 55 61
14. M.D. Laird, J.S. Shields, S. Sukumari-Ramesh, D.E. Kimbler, R.D. Fessler, B. Shakir, P. Youssef, N. Yanasak, J.R. Vender, and K.M. Dhandapani High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4 Glia 62 2014 26 38
15. W. Li, H.P. Ling, W.C. You, H.D. Liu, Q. Sun, M.L. Zhou, W. Shen, J.B. Zhao, L. Zhu, and C.H. Hang Elevated cerebral cortical CD24 levels in patients and mice with traumatic brain injury: a potential negative role in nuclear factor kappa b/inflammatory factor pathway Mol. Neurobiol. 49 2014 187 198
16. A.I. Maas, A. Marmarou, G.D. Murray, and E.W. Steyerberg Clinical trials in traumatic brain injury: current problems and future solutions Acta Neurochir. Suppl. 89 2004 113 118
17. S.S. Mao, R. Hua, X.P. Zhao, X. Qin, Z.Q. Sun, Y. Zhang, Y.Q. Wu, M.X. Jia, J.L. Cao, and Y.M. Zhang Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-kappaB pathway J. Neurotrauma 29 2012 1941 1959
18. N. Marklund, and L. Hillered Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? Br. J. Pharmacol. 164 2011 1207 1229
19. N. Matsunaga, N. Tsuchimori, T. Matsumoto, and M. Ii TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules Mol. Pharmacol. 79 2011 34 41
20. K.W. McConeghy, J. Hatton, L. Hughes, and A.M. Cook A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury CNS Drugs 26 2012 613 636
21. T.W. Rice, A.P. Wheeler, G.R. Bernard, J.L. Vincent, D.C. Angus, N. Aikawa, I. Demeyer, S. Sainati, N. Amlot, C. Cao, M. Ii, H. Matsuda, K. Mouri, and J. Cohen A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis Crit. Care Med. 38 2010 1685 1694
22. H. Sakurai Targeting of TAK1 in inflammatory disorders and cancer Trends Pharmacol. Sci. 33 2012 522 530
23. T. Sha, M. Sunamoto, T. Kitazaki, J. Sato, M. Ii, and Y. Iizawa Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model Eur. J. Pharmacol. 571 2007 231 239 (Pubitemid 47379694)
24. J.H. Shim, C.C. Xiao, A.E. Paschal, S.T. Bailey, P. Rao, M.S. Hayden, K.Y. Lee, C. Bussey, M. Steckel, N. Tanaka, G. Yamada, S. Akira, K. Matsumoto, and S. Ghosh TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo Genes Dev. 19 2005 2668 2681 (Pubitemid 41627934)
25. Y. Suzuki, K. Hattori, J. Hamanaka, T. Murase, Y. Egashira, K. Mishiro, M. Ishiguro, K. Tsuruma, Y. Hirose, H. Tanaka, S. Yoshimura, M. Shimazawa, N. Inagaki, H. Nagasawa, T. Iwama, and H. Hara Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia Sci. Rep. 2 2012 896
26. C.M. Tolias, and M.R. Bullock Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx 1 2004 71 79 (Pubitemid 46589341)
27. Y.C. Wang, P.F. Wang, H. Fang, J. Chen, X.Y. Xiong, and Q.W. Yang Toll-like receptor 4 antagonist attenuates intracerebral hemorrhage-induced brain injury Stroke 44 2013 2545 2552
28. Y. Xiong, A. Mahmood, and M. Chopp Emerging treatments for traumatic brain injury Expert Opin. Emerg. Drugs 14 2009 67 84
29. D. Zhang, Y. Hu, Q. Sun, J. Zhao, Z. Cong, H. Liu, M. Zhou, K. Li, and C. Hang Inhibition of transforming growth factor beta-activated kinase 1 confers neuroprotection after traumatic brain injury in rats Neuroscience 238 2013 209 217
30. Z. Zhao, D.J. Loane, M.G. Murray 2nd, B.A. Stoica, and A.I. Faden Comparing the predictive value of multiple cognitive, affective, and motor tasks after rodent traumatic brain injury J. Neurotrauma 29 2012 2475 2489